Biologics Drug / Agent News and Research

RSS
Biologics prescribers collaborative releases new white paper: The State of Biosimilars Policy

Biologics prescribers collaborative releases new white paper: The State of Biosimilars Policy

SP Industries acquires privately held Stability Environments

SP Industries acquires privately held Stability Environments

BioCision announces ThawSTAR™ automated sample thawing system

BioCision announces ThawSTAR™ automated sample thawing system

Treating ulcerative colitis and Crohn’s disease

Treating ulcerative colitis and Crohn’s disease

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

VENADO bone graft systems launched by K2M

VENADO bone graft systems launched by K2M

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Regenerative medicine: an interview with Christophe Dardel, President of DSM Biomedical

Regenerative medicine: an interview with Christophe Dardel, President of DSM Biomedical